On November 28th, our CEO, Dr. Stéphanie Boutillier, was honored to speak at “Meet&Match”, a networking event hosted by BioValley France and BIOPRO Baden-Württemberg GmbH in Strasbourg. This year’s edition focused on gender medicine and brought together leading minds to tackle today’s most pressing health challenges.
Our CEO’s talk focused on an important yet often overlooked topic: gender differences in neurodegenerative diseases, with a focus on Alzheimer. These differences influence not only how diseases develop but also how they progress, underscoring the need for more personalized approaches to care.
She highlighted NeuroDeGene® tool, our advanced DNA sequencing panel that’s reshaping how we approach these diseases.
NeuroDeGene®:
- Creates predictive models for historically hard-to-diagnose conditions using cutting-edge sequencing, bioinformatics, and machine learning.
- Includes 15,533 variants across 19 diseases, with 70% of the panel focused on non-coding variants—critical drivers of disease.
- Supports diagnosis, prognosis, and individualized treatments, paving the way for better outcomes.
Events like Meet&Match reinforce our commitment to driving innovation and fostering collaboration in neuroscience. With our NeuroDeGene® product, we’re proud to play a role in advancing understanding and improving lives.